Trial: 202108212

Phase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients with Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-deficient Gastrointestinal Stromal Tumor (GIST)

Phase

II

Principal Investigator

Van Tine, Brian

Disease Site

Soft Tissue

Learn more about this study at: clinicaltrials.gov